'More May Be Less' in Metastatic Cervical Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

VIENNA--A new study from the EORTC Gynecologic Cancer Cooperative Group (GCCG) has challenged the assumption that aggressive combination chemotherapy is worthwhile in chemotherapy-naïve women with metastatic squamous cell cancer of the cervix.

VIENNA--A new study from the EORTC Gynecologic Cancer Cooperative Group(GCCG) has challenged the assumption that aggressive combination chemotherapyis worthwhile in chemotherapy-naïve women with metastatic squamouscell cancer of the cervix.

Although a highly active four-drug combination yielded a response ratesuperior to that seen with cisplatin alone, it resulted in substantiallygreater hematologic and nonhematologic toxicity, and afforded no survivaladvantage, Dr. Jan Vermorken of Amsterdam's Free University Hospital, saidat the European Society for Medical Oncology Congress.

The study documented a 31% response rate in the 143 women assigned toBEMP (bleomycin, vindesine, mitomycin C, cisplatin) versus 19% in the 144platinum-treated patients.

This benefit was achieved at the cost of more frequent complications,treatment delays, and dose reductions. At 6 years' follow-up, survivalcurves for the two regimens were superimposable.

Recent Videos
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
ctDNA reductions or clearance also appeared to correlate with a decrease in disease burden during the pre-boost phase of radiotherapy.
Investigators evaluated ctDNA as a potentially noninvasive method to predict response to radiotherapy among those with gynecologic malignancies.
The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.
Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.
Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.